NASDAQ : STLN
Starling Oncology, Inc. — Key statistics
Healthcare · Medical Care Facilities · United States
Last price 6.65 USD (Oct 29, 2026, 4:00 PM EDT) · Market cap 677.74M
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Key statistics
Valuation
| Measure | Value |
|---|
| Market Cap | 665.51M |
| Enterprise Value | 729.21M |
Dates
| Measure | Value |
|---|
| Earnings Date | Nov 5, 2026 |
| Ex-Dividend Date | n/a |
Shares
| Measure | Value |
|---|
| Current Share Class | 101.92M |
| Shares Outstanding | 101.92M |
| Shares Change (YoY) | +25.63% |
| Shares Change (QoQ) | +1.21% |
| Owned by Insiders (%) | 12.78% |
| Owned by Institutions (%) | 49.19% |
| Float | 88.89M |
Ratios
| Measure | Value |
|---|
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 1.13 |
| Forward PS | 0.87 |
| PB Ratio | n/a |
| P/TBV Ratio | n/a |
| P/FCF Ratio | n/a |
| P/OCF Ratio | 2,029.00 |
| PEG Ratio | n/a |
Evratios
| Measure | Value |
|---|
| EV / Earnings | n/a |
| EV / Sales | 1.24 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financialposition
| Measure | Value |
|---|
| Current Ratio | 1.36 |
| Quick Ratio | 1.14 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -3.42 |
Financialefficiency
| Measure | Value |
|---|
| Return on Equity (ROE) | n/a |
| Return on Assets (ROA) | -9.65% |
| Return on Invested Capital (ROIC) | -30.31% |
| Return on Capital Employed (ROCE) | -31.32% |
| Weighted Average Cost of Capital (WACC) | 6.45% |
| Revenue Per Employee | $916,137 |
| Profits Per Employee | -$47,680 |
| Employee Count | 641 |
| Asset Turnover | 3.47 |
| Inventory Turnover | 27.66 |
Taxes
| Measure | Value |
|---|
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stockprice
| Measure | Value |
|---|
| Beta (5Y) | 0.42 |
| 52-Week Price Change | +38.94% |
| 50-Day Moving Average | 6.47 |
| 200-Day Moving Average | 4.70 |
| Relative Strength Index (RSI) | 49.46 |
| Average Volume (20 Days) | 1,262,253 |
Shortselling
| Measure | Value |
|---|
| Short Interest | 6.54M |
| Short Previous Month | 6.79M |
| Short % of Shares Out | 6.41% |
| Short % of Float | 7.35% |
| Short Ratio (days to cover) | 4.75 |
Incomestatement
| Measure | Value |
|---|
| Revenue | 587.24M |
| Gross Profit | 92.17M |
| Operating Income | -26.09M |
| Pretax Income | -36.29M |
| Net Income | -30.56M |
| EBITDA | -19.28M |
| EBIT | -26.09M |
| Loss Per Share | -$0.30 |
Balancesheet
| Measure | Value |
|---|
| Cash & Cash Equivalents | 41.09M |
| Total Debt | 104.79M |
| Net Cash | -63.70M |
| Net Cash Per Share | -$0.63 |
| Equity (Book Value) | -24.91M |
| Book Value Per Share | -0.25 |
| Working Capital | 34.05M |
Cashflow
| Measure | Value |
|---|
| Operating Cash Flow | 328,000 |
| Capital Expenditures | -3.61M |
| Depreciation & Amortization | 6.81M |
| Net Borrowing | -1.13M |
| Free Cash Flow | -3.29M |
| FCF Per Share | -$0.03 |
Margins
| Measure | Value |
|---|
| Gross Margin | 15.69% |
| Operating Margin | -4.44% |
| Pretax Margin | -6.18% |
| Profit Margin | -6.18% |
| EBITDA Margin | -3.28% |
| EBIT Margin | -4.44% |
| FCF Margin | n/a |
Dividends
| Measure | Value |
|---|
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | -25.63% |
| Shareholder Yield | -25.63% |
| Earnings Yield | -4.66% |
| FCF Yield | -0.49% |
Analystforecasts
| Measure | Value |
|---|
| Price Target | $9.40 |
| Price Target Difference | 43.95% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 5 |
| Revenue Growth Forecast (3Y) | 31.36% |
| EPS Growth Forecast (3Y) | n/a |
Stocksplits
| Measure | Value |
|---|
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Measure | Value |
|---|
| Altman Z-Score | 1.84 |
| Piotroski F-Score | 4 |
Fairvalue
| Measure | Value |
|---|
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |